Basal Ganglia Diseases
Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
Subtype terms (12)
More specific conditions that are subtypes of Basal Ganglia Diseases in the MeSH hierarchy.
- Basal Ganglia Cerebrovascular Disease
- Chorea Gravidarum
1 drug experimental
- Dystonia Musculorum Deformans
- Hepatolenticular Degeneration
23 drugs (11 approved, 12 experimental)
- Huntington Disease
97 drugs (44 approved, 53 experimental)
- Meige Syndrome
2 drugs (1 approved, 1 experimental)
- Multiple System Atrophy
65 drugs (36 approved, 29 experimental)
- Neuroleptic Malignant Syndrome
- Pantothenate Kinase-Associated Neurodegeneration
2 drugs (1 approved, 1 experimental)
- Parkinsonian Disorders
54 drugs (23 approved, 31 experimental)
- Supranuclear Palsy, Progressive
51 drugs (24 approved, 27 experimental)
- Tourette Syndrome
49 drugs (31 approved, 18 experimental)
Drugs by status
Approved for this indication (1)
Phase 4 trials (5)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 1 Indications (2)